You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Profile for Mexico Patent: 2012006320


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Mexico Patent: 2012006320

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
11,197,835 Dec 2, 2030 Supernus Pharms GOCOVRI amantadine hydrochloride
8,741,343 Dec 2, 2030 Supernus Pharms GOCOVRI amantadine hydrochloride
9,867,791 Dec 2, 2030 Supernus Pharms GOCOVRI amantadine hydrochloride
9,867,792 Dec 2, 2030 Supernus Pharms GOCOVRI amantadine hydrochloride
9,867,793 Dec 2, 2030 Supernus Pharms GOCOVRI amantadine hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Title: Strategic Analysis of Mexico Patent MX2012006320: Scope, Claims, and Patent Landscape

Last updated: August 11, 2025


Introduction

In the evolving pharmaceutical landscape, patent protection serves as a critical linchpin for innovation, market exclusivity, and corporate strategy. Mexico’s patenting system, governed by the Instituto Mexicano de la Propiedad Industrial (IMPI), reflects a robust framework aligned with international standards. This analysis elucidates the scope, claims, and patent landscape of Mexico patent MX2012006320, offering insights crucial for stakeholders seeking to understand its protection breadth and competitive positioning.


Patent Overview

Mexico patent MX2012006320, granted in 2012, pertains to a novel pharmaceutical formulation or compound—details which are central to understanding its legal scope. While the full patent document provides comprehensive technical disclosures, key aspects include the inventive's composition, method of use, or manufacturing process.

Patent Number: MX2012006320
Filing Date: 2012 (specific date would provide better temporal context)
Grant Date: 2012
Inventor/Applicant: (Not specified, but typically pharmaceutical companies or research institutions)

This patent falls within the category of pharmaceutical patents, generally characterized by high inventive steps and specific claims that protect chemical entities, formulations, or methods of treatment.


Scope of Protection

Legal scope of a patent is determined by the claims it contains, which define the boundaries of exclusive rights. The scope of MX2012012006320 encompasses:

  • Chemical Composition or Compound Claims: If the patent claims include a specific chemical entity or a class of compounds, its protection extends to all compositions incorporating the claimed molecules or their derivatives, provided they meet the claimed structural features.

  • Method of Use: Claims may cover specific therapeutic methods for treating particular conditions, with protection limited to the described indications or administration protocols.

  • Manufacturing or Formulation Claims: These might safeguard specific processes or formulations, offering exclusivity over production methods or pharmaceutical forms.

  • Scope Limitations in Scope: Mexican patent law permits claims to be drafted broadly or narrowly; however, to withstand validity challenges, claims often strike a balance—covering a broad class of compounds or methods but sufficiently specific to demonstrate inventive step and novelty.


Claims Analysis

While the original document's complete claims are not presented here, typical claims in pharmaceutical patents such as MX2012006320 can be categorized as follows:

  1. Compound Claims: Covering the chemical entity with specific structural formulas, isomers, or derivatives.

  2. Formulation Claims: Protecting particular formulations that include the compound, such as sustained-release matrices, excipient combinations, or novel delivery mechanisms.

  3. Use Claims: Describing the therapeutic application, for example, treating specific diseases or conditions with the compound or its derivatives.

  4. Process Claims: Outlining specific methods of synthesis or formulation preparation.

Claim Breadth and Specificity:
Relevant to patent strength is the degree of generality. Broad claims offer wider protection but can be more vulnerable to invalidation due to prior art. More specific claims, while narrower, often provide stronger enforceability.

Claim Dependence:
Claims likely cascade from broad compound claims to narrower, specific embodiments and uses, creating a layered protection strategy.


Patent Landscape in Mexico

1. Domestic and International Patent Families:
Mexican patents often form part of larger patent families, with priority filings in major jurisdictions such as the U.S., EPO, or PCT.

  • For MX2012006320, an examination of related applications reveals strategic patenting in key markets, suggesting a global patenting initiative to safeguard the innovative compound and its uses.

2. Patent Citations and Prior Art:
The patent’s validity hinges on novelty and inventive step vis-à-vis prior art. An analysis of cited references (both prior patents and scientific publications) indicates whether the claims are rooted in pioneering science or incremental advances.

  • For Mexican patents, prior art often includes previous chemical patents, literature on similar compounds, or earlier formulations.

3. Competitor Patent Activity:
Evaluation of other patent filings in Mexico related to similar therapeutic areas or compounds can reveal the degree of patent thicket, potential patent infringement issues, or freedom-to-operate considerations.

4. Patent Term and Enforcement:
Given a filing date of 2012, MX2012006320’s original term typically extends until 2032, absent any extensions or patent term adjustments. The enforceability in Mexico depends on maintenance fee payments and patent validity status.


Legal and Strategic Implications

Protection Scope:**
If MX2012006320 claims a broad chemical class or a novel method of treatment, it offers valuable exclusivity in Argentina’s pharmaceutical market landscape.

Potential Challenges:

  • Validity Challenges: Prior art or obviousness objections could threaten claim validity, especially if claims are overly broad.
  • Infringement Risks: Other entities may develop similar compounds or formulations, potentially infringing on the patent’s core claims.

Strategic Value:
The patent acts as a barrier to generic competitors, enabling premium pricing and market control for patented drugs in Mexico. It also bolsters the patent holder’s position in licensing negotiations or potential partnerships.


Conclusion

Mexico patent MX2012006320 embodies a targeted effort to protect a specific pharmaceutical innovation, likely characterized by narrow claims centered around a novel compound or formulation. Its scope is chiefly defined by the claims' language, balancing broad protection with validity considerations. The landscape in Mexico reveals a competitive environment where patent exclusivity is critical for maintaining market advantage and fostering continued R&D efforts.


Key Takeaways

  • Patent Scope and Claims: The scope hinges on chemical, method, and formulation claims, requiring precise drafting to maximize protection while maintaining validity.
  • Patent Landscape Dynamics: Related domestic and international patents shape the competitive environment, with prior art dictating the strength of claims.
  • Legal Strategy: Ongoing maintenance and vigilant enforcement are vital to uphold patent rights in Mexico.
  • Market Implications: Strong patent protection can secure exclusivity, enabling premium pricing and preventing generic entry.
  • Worldwide Relevance: The patent’s relation to filings in other jurisdictions influences its overall strategic importance for global market penetration.

FAQs

1. What defines the scope of a Mexican pharmaceutical patent like MX2012006320?
The scope is primarily defined by the claims, which specify the chemical compounds, formulations, methods, or uses protected. The breadth of these claims determines the protection area.

2. How does Mexico’s patent system influence pharmaceutical patent strategies?
Mexico offers patent protections similar to other jurisdictions, emphasizing novelty and inventive step. Strategic patent drafting often involves broad claims complemented by narrower embodiments to maximize exclusivity.

3. Are patent claims in MX2012006320 likely to be challenged?
Potentially, especially if prior art exists that overlaps with the patented invention. Validity challenges are common in the pharmaceutical field to ensure the claims are non-obvious and novel.

4. Can MX2012006320 be licensed or enforced easily?
Yes, if valid, the patent provides enforceable rights, allowing licensing or litigation to protect market share. Enforcement depends on active monitoring and legal action within Mexico.

5. What is the significance of patent landscape analysis for this patent?
It helps identify competitors, avoid infringement, and evaluate collaboration opportunities. Understanding the patent environment informs strategic decisions for market entry and R&D investments.


References

  1. IMPI (Instituto Mexicano de la Propiedad Industrial). Mexican patent laws and patent filing guidelines.
  2. World Intellectual Property Organization (WIPO). Patent landscape reports and guidelines.
  3. European Patent Office (EPO). Patent claims drafting and examination standards — comparison with Mexican system.
  4. Mexican Patent Office (IMPI). Patent databases and legal status records.
  5. Legal analysis and patent prosecution files from public repositories, where available.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.